ConductScience.org, home

Comparison · NCT00047008-sae

Standard Fractionation RT + Cisplatin vs Accelerated Fractionation RT + Cisplatin: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Standard Fractionation RT + Cisplatin vs Accelerated Fractionation RT + Cisplatin: serious adverse events. Trial comparisons, record NCT00047008-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00047008-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.8120.7680.849wilson
Risk in group 20.7750.7290.815wilson
Risk difference, group 1 minus group 20.0366-0.02260.0956newcombe hybrid score
Risk ratio, group 1 over group 21.050.9721.13log
Odds ratio, group 1 over group 21.250.8711.8log
Number needed to harm, for one more participant with a serious adverse event on Standard Fractionation RT + Cisplatin than on Accelerated Fractionation RT + Cisplatin27.3from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Standard Fractionation RT + CisplatinStandard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.293361EG000
Group 2Accelerated Fractionation RT + CisplatinAccelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.279360EG001

Harm

What it counts
Total, serious adverse events
Time frame

Source ClinicalTrials.gov

Trial

Title
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
NCT number
NCT00047008
Phases
PHASE3
Conditions
Head and Neck Cancer
Interventions
cisplatin, Standard fractionation RT, Accelerated fractionation radiation therapy, Conventional surgery for select patients
Lead sponsor
Radiation Therapy Oncology Group
Results first posted
2014-08-15

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00047008-sae